|
|||||
|
|
Safety and efficacy of ertugliflozin in Asian patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: VERTIS Asia |
|
| Authors: | Linong Ji MD Yanmei Liu MD Heng Miao MD Yongli Xie MD Ming Yang MD Wei Wang MD Yuting Mu MD Ping Yan PhD Sharon Pan PhD Brett Lauring MD Shu Liu MD Susan Huyck DrPH Yanping Qiu MS Steven G Terra PhD |
| Institution: | 1. Peking University People's Hospital, Beijing, China;2. Yancheng First People's Hospital, Yancheng, China;3. The Second Affiliated Hospital of Nanjing Medical University, Nanjing, China;4. Pingxiang People's Hospital, Pingxiang, China;5. Pfizer (China) R&D Co., Shanghai, China;6. Pfizer Inc., New York, New York;7. MSD China, Beijing, China;8. Merck & Co., Inc., Kenilworth, New Jersey;9. Pfizer Inc., Andover, Massachusetts |
| Abstract: | |
| Keywords: | Asia ertugliflozin SGLT2 inhibitor type 2 diabetes mellitus |